English

Results Third Quarter 2007

Report this content
Oslo, Norway, 26 October 2007


Photocure ASA (Oslo Stock Exchange: PHO) presents today its results for the third quarter of 2007. The main items of the report are:
  
  •         Sales revenues in the quarter amounted to NOK 15.6 million (14.6), an increase of 7 %.
  •         Sales revenues YTD amounted to NOK 51.7 million (39.5), an increase of 31 %.
  •         All R&D projects are on schedule. The R&D expenses were NOK 28.7 million (18.8).
  •         Net loss amounted to NOK -23.6 million (-11.8).
  •         Liquid assets amounted to NOK 271.7 million at the end of the period.


    • President and CEO of Photocure, Dr. Kjetil Hestdal, says in a comment to the results: "All clinical development projects are progressing to plan. However, we are not satisfied with our sales of Metvix outside the Nordic region in third quarter and will take action to improve this."


     


    For further information, please contact:
     
    President and CEO Kjetil Hestdal
    E-mail: kh@photocure.no
    Mobile: +47 913 19 535
     
    CFO Christian Fekete
    E-mail: cf@photocure.no
    Mobile: +47 916 42 938
     
    www.photocure.com
     
     
    Photocure ASA is a Norwegian pharmaceutical company listed on the Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of different types of cancer.
     
    Photocure® has three products on the market: Metvix® cream combined with the Aktilite® lamp for the treatment of sun-damaged skin and certain types of skin cancer, and Hexvix® for the diagnosis of bladder cancer. In addition, the company has several follow-on products and technologies in the pipeline.

    Subscribe

    Documents & Links